Change Control Mapping: MFDS, EU MDR, and FDA Compared

Why This Matters

Multinational medical device manufacturers face change control complexity:

• Same change may require different actions per jurisdiction
• Conflicting timelines (e.g., MFDS 30 days, FDA 30 days but different scope)
• Resource allocation across regulatory affairs teams
• Risk of missing required notification in one jurisdiction

A unified change classification framework — feeding jurisdiction-specific outputs — is operationally efficient.

The 3-Tier Classification (Adapted)

Tier 1: Internal Documentation Only

Changes that do not affect device safety, performance, intended use, or essential design.

MFDS: Internal change log only EU MDR: Internal Quality Management System change log FDA: Internal change record per 21 CFR 820.30(i)

Examples:

• Manufacturing instruction clarifications (no process change)
• Cosmetic packaging updates (no label content change)
• Minor SOP rewording (no procedure change)

Tier 2: Notification Required

Changes affecting non-essential aspects of safety, performance, or labeling.

Jurisdiction	Required Filing	Timeline
MFDS	Change notification (변경신고/변경허가)	30 days from implementation
EU MDR	Notified Body notification	Before implementation (typically)
FDA	510(k) Special, or letter to file (case-dependent)	Pre-implementation (Special 510(k))

Examples:

• Manufacturing site address change (same site)
• Software updates without algorithm change
• Korean labeling text updates
• Accessory additions
• Non-critical supplier change

Tier 3: New Submission Required

Changes affecting essential design, intended use, performance, or safety.

Jurisdiction	Required Filing	Timeline
MFDS	New registration (신규허가)	Before implementation
EU MDR	Significant change → new conformity assessment	Before implementation
FDA	New 510(k), De Novo, or PMA supplement	Before implementation

Examples:

• New indications
• Patient population change
• Algorithm replacement (AI/ML SaMD)
• Manufacturing site change (different site)
• Sterilization method change
• Patient-contacting material change

Jurisdiction-Specific Considerations

MFDS Korea

• Filing through KLH (Korea License Holder)
• 30-day post-implementation timeline for Tier 2
• Pre-approval required for Tier 3
• Korean translation of change description required
• KGMP impact assessment for manufacturing changes

EU MDR

• Notified Body engagement for significant changes
• Substantial change → modification of conformity certificate
• PMS plan impact assessment
• Eudamed updates

FDA

• Special 510(k) for documented design changes (modular review)
• Traditional 510(k) for significant changes
• PMA supplements for Class III devices
• Risk-based approach to change reporting

Change Classification Decision Matrix

For each proposed change, evaluate:

Question	If YES	If NO
Affects intended use?	Tier 3	Continue
Affects safety profile?	Tier 3	Continue
Affects performance specifications?	Tier 3	Continue
Changes manufacturing site?	Tier 3 (MFDS), Tier 3 (FDA)	Continue
Affects labeling content?	Tier 2	Continue
Algorithm tuning within PCCP?	Tier 2 (FDA/MFDS), Tier 3 (no PCCP)	Continue
Process change (validated)?	Tier 2 (MFDS), Tier 1-2 (FDA)	Tier 1
Document clarification?	Tier 1	N/A

Unified Change Control Workflow

Step 1: Change Initiation

• Change description documented
• Affected products identified
• Proposed implementation date

Step 2: Classification Assessment

For each jurisdiction where device is registered:

• MFDS classification (Tier 1/2/3)
• EU MDR classification (Tier 1/2/3)
• FDA classification (Tier 1/2/3)
• Other jurisdictions as applicable

Output: Multi-jurisdiction classification matrix.

Step 3: Filing Strategy

Based on classification:

• If all Tier 1: Internal log; implement
• If any Tier 2: Coordinated filing timeline per jurisdiction
• If any Tier 3: Approval-before-implementation; longest jurisdiction drives timeline

Step 4: Filing Execution

• MFDS: Through KLH
• EU MDR: Through Notified Body
• FDA: Direct submission or letter to file

Step 5: Implementation

• Tier 1: Immediate implementation
• Tier 2: Per jurisdiction-specific timing (typically post-filing for MFDS, pre-implementation for FDA)
• Tier 3: After all required approvals

Step 6: Post-Implementation Verification

• Confirm change implemented per approval scope
• Update internal change log
• Update affected documentation
• Inform KLH and other regional representatives

Common Multi-Jurisdiction Patterns

Pattern 1: Same Change, Different Classification

Software security patch (CVE fix):

• MFDS: Tier 2 (per 2026 guidance)
• FDA: Often Tier 1 (Letter to File) or Tier 2 (Special 510(k))
• EU MDR: Tier 1-2 depending on PMS plan

Strategy: File MFDS Tier 2 notification; document for FDA/EU.

Pattern 2: Manufacturing Site Change

Adding second manufacturing site:

• MFDS: Tier 3 (new KGMP + new registration)
• FDA: Tier 2 (Special 510(k)) or Tier 3 (depending on QSR)
• EU MDR: Significant change requiring Notified Body involvement

Strategy: Coordinate timeline; MFDS typically longest path.

Pattern 3: AI/ML Algorithm Update

Within PCCP scope:

• MFDS: Tier 2 (notification, per 2025 guidance)
• FDA: Tier 1-2 (within PCCP scope)
• EU MDR: Per established change control plan

Outside PCCP scope:

• All jurisdictions: Tier 3

Strategy: Robust PCCP at initial submission minimizes future change burden.

Pattern 4: New Indication

• All jurisdictions: Tier 3
• Coordinate global submission strategy
• May require additional clinical data

Cost Comparison by Tier

Tier	MFDS Cost	EU MDR Cost	FDA Cost
Tier 1	$0 (internal)	$0 (internal)	$0 (internal)
Tier 2	$3K–$10K	$5K–$20K	$7K–$15K (Special 510(k))
Tier 3	$15K–$40K + 6+ months	$30K–$100K + 6–12 months	$30K–$50K + 6–12 months

Per-change costs add up rapidly; correct classification is financially important.

Frequently Asked Questions

Q: What if classifications differ between jurisdictions?

A: Apply each jurisdiction's classification independently. Same change can be Tier 2 in MFDS and Tier 1 in FDA. Filing handled per local rules.

Q: Can we have a single global change control system?

A: Yes. Unified change initiation → jurisdiction-specific classification and filing outputs. Most efficient model.

Q: How does Leanabl help with multi-jurisdiction change control?

A: Leanabl's Change Notification Management service handles Korean change classification and filing, often coordinated with global regulatory affairs teams.

Q: What if our change might require FDA pre-approval but MFDS notification only?

A: FDA approval typically takes 90+ days; MFDS notification can be filed within 30 days. Strategy: Coordinate so FDA approval received before MFDS implementation. Implement globally after all approvals.

Q: Are there changes that don't require any filing anywhere?

A: Yes — Tier 1 internal changes. Always document internally for QMS traceability.

How Leanabl Helps

• Change Notification Management — Korean change classification and filing
• Korea Design Lock — design freeze with change-aware planning
• License Compliance Update — historical change backlog cleanup

Contact Leanabl for change control strategy.

---

Last updated: 2026-05-15.